TAK trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TAK achieves its forward estimates and maintains a stable P/E multiple of 0.3x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Takeda Pharmaceutical Company Limited (TAK) has a Wall Street consensus price target of N/A, based on estimates from 6 covering analysts. The company has a market capitalization of $48.84B.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TAK trades at a trailing P/E of 39.3x and forward P/E of 0.3x. Analysts expect EPS to grow -4.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $2706.42, with bear and bull scenarios of $1705.05 and $3565.98 respectively. Model confidence stands at 49/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVONovo Nordisk A/S | $191.9B | $43.19 | $45.00 | +4.2% | Buy | 2.0x | 39 |
AZNAstraZeneca PLC | $271.2B | $174.93 | $186.67 | +6.7% | Buy | 17.0x | 41 |
SNYSanofi | $102.4B | $42.38 | $51.00 | +20.3% | Buy | 10.1x | 27 |
NVSNovartis AG | $280.6B | $147.08 | $170.00 | +15.6% | Hold | 16.9x | 25 |
GSKGSK plc | $101.9B | $50.67 | $52.45 | +3.5% | Hold | 14.0x | 29 |
ABBVAbbVie Inc. | $383.2B | $216.63 | $256.92 | +18.6% | Buy | 15.2x | 41 |
BMYBristol-Myers Squibb Company | $110.3B | $54.00 | $62.60 | +15.9% | Hold | 8.5x | 41 |
JNJJohnson & Johnson | $550.4B | $228.39 | $251.55 | +10.1% | Buy | 19.7x | 40 |
MRKMerck & Co., Inc. | $281.2B | $113.87 | $131.58 | +15.6% | Buy | 22.2x | 37 |
PFEPfizer Inc. | $143.5B | $25.22 | $26.75 | +6.1% | Hold | 8.5x | 39 |
Quick answers to the most common questions about buying TAK stock.
The consensus price target for TAK is $N/A, close to the current price of $15.63 (N/A% implied move). Based on 6 analyst estimates, the stock appears fairly valued near current levels.
TAK has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
With a forward P/E of 0.2659x, TAK trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $N/A for TAK, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $3566 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
TAK is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TAK stock forecast based on 6 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $2706, with bear/bull scenarios of $1705/$3566.
Our quantitative valuation model calculates TAK's fair value at $2706 (base case), with a bear case of $1705 and bull case of $3566. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.
TAK trades at a forward P/E ratio of 0.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 39.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
TAK appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TAK analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $1705-$3566 range provides an independent fundamental perspective.
Deep dive into TAK consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.